The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Q3 2023 - $8,500,000
Q4 2023 - $14,500,000
Q1 2024- $15,000,000
Q2 2024 -$16,500,000
Q3 2024 - $22,500,000
Q4 2024 - $31,500,000
Q1 2025 - $38,900,000
Looks ok to me :)
Q2 2025+
$45,700,000
HarChris: Like you, I see nothing in this update to justify the optimism shown by a couple of the other posters.
It is, however, consistent with how this operation rolls though.
Still very much on track to end up how I suggested this one is likely to.
Did I miss the part about what action they have taken against that third party, who they previously blamed for those false prescription numbers? Or has it all been forgiven and forgotten? Lol.
A zombie outfit, to all intents and purposes in my sincere opinion - but this is AIM, so who knows, the SP might have a spike.
This is a terrible update, not sure where the positives are. A 1% quarterly increase in prescriptions, based on a disappointing Q4 2023 too, is terrible. This needs to be growing c50% minimum. We were meant to be at 50k per quarter 6 months ago. Still miles off.
CEO is clearly clueless, and has an excuse for everything.
$10m of cash will clearly not last the year
Yes but they have got backers to handle it, which normal for a healthy growing company!
EV includes debt, Shield only have cash because they keep taking on more debt. The EV isn't increasing.
How can market cap be same as cash , basically no value is being given for EV .
Compare the sales to previous year, huge increase in sales . Yet the price is down here .
You might just be being naive but Shield is 'not doing a lot better than many other Aim companies' , at this stage revenue is irrelevant, they were on a path to profitability and now they are MILES away - they are burning cash like nobody's business and have a mcap of £10m to raise against vs a £100m mcap last year.
The debt facility gives them another quarter to show some significant improvement but if nothing seen them it must surely be curtains.
Very happy to see the comments about the debt facility. They will get there in the end I think
It may not be as fast but there is growth and Shield is doing a lot better than many other AIM companies with only a speculative higher SP which have yet to make any income.
SP is a bargain imo.
The real increase is 1% on Q4 2023 - for a company supposedly targeting 330k prescriptions in 2024 28.8k is a rubbish number and provides conclusive proof that growth is no longer on track.
This is going to rocket up today!
''Need to see 45k scripts for 1st qtr 24 to get this back on track along with a reduction in monthly costs.
It will be tight.''
_______________
Traxpern, happy with 28800? Hardman research had 65k scripts at this stage.
There are 775M shares in issue so 3.5M is only 0.4% of the company, wouldn't require a TR1 unless someone was crossing a threshold at or above 3%.
I've decided to stay on the sidelines but tomorrow will indeed be interesting.
There were lots of massive block selling in last few months too but no TR1 was issued. Once it was 3.5M shares sold in one go but no TR1 or as such. This company has a history to not sharing important information with the market on time hence my comments about tomorrow. In this market you can't take anything for granted. Remember C4XD, TWD, AMTE etc? Better to be safe than sorry. GL anyway
I hope 100%. also there seems to be block buyer, wonder if we will see a TR1 rns soon...
Either it's gonna jump over 100% with solid positive outlook news or crash 50-60% with their typical dry rampy updates. Eitherway it's gonna be really interesting.
GLA
Great day
I hope they do. Looks like some shorts also closing so good luck to all the long suffering shareholders.
Whatever happens, as near to 100% STX will be relying on cash to get them though the rest of 2024 so the question is who provides it? AOP? This is an FDA approved drug so if it is as good as the mgmt team claim it to be it's obviously worth something, the problem is they won't be able to fight off a lowball bid from the likes of AOP this time around.
Last year the mandatory cash offer was 6.01p, this time around they could easily pull off a TO at less than half that.
Results!
Who things thats the results will be stunning & shock us all in a good way?.
Just remember its this management that have missed targets, breached promises, fund raises at 30p, 15p and 6p who would actually believe a thing they say?
I understand we had an alleged pandemic which basically closed Sheilds marketplace for several years.
Before that this management team thought they could go and conquer the USA alone and that went tits up. How in anyone's mind thought it would be a good idea to take this drug into the states and hope to crack it? Eventually after lost time, effort & money did someone see sence and go 50/50 with a partner.
The list of shambolic management decisions is appalling.
Can the management pull a rabbit out of the hat?
In all honesty, I hope so buf doubt it.
GLA, DYOR & have a great weekend
Neon,
That's it, there or thereabouts as far as we will ever know.
There must be a total step change in company spend verses revenue intake for sheild to stay in ICU & not moved to the mortuary for buriel.
Nice! But there was a big sell too, £1.13M. I've noticed lots of big sells in last few weeks with big buys, not sure what's going on. If buyers can overcome the sellers than it might rise, something it's been doing since touching 1.06p yesterday. I hope they can finally bring some good news next week but judging by what they have done before, I'll wait and see the result first and actions they are taking to mitigate their financial catastrophe.
GLA
Is it? So please confirm if I'm doing it right. 20/12 = £1.66M per month? Four months gone almost so £6.67M spent already so £13M-£6.67M = £6.33M left in the bank which will last £6.33M/£1.66M = 4 months approximately so they will run out of cash around August 2024?
Flurry of buys....lol.
The poor people 6p will be so excited they'll be opening wine all weekend
Flurry of buys